Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ELAN 
Elanco Animal Health (ELAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ELAN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.86
1 Year Target Price $14.86
| 6 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.36% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.10B USD | Price to earnings Ratio 19.04 | 1Y Target Price 14.86 |
Price to earnings Ratio 19.04 | 1Y Target Price 14.86 | ||
Volume (30-day avg) 15 | Beta 1.68 | 52 Weeks Range 8.02 - 15.78 | Updated Date 06/30/2025 |
52 Weeks Range 8.02 - 15.78 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.43% | Operating Margin (TTM) 10.14% |
Management Effectiveness
Return on Assets (TTM) 1.14% | Return on Equity (TTM) 6.01% |
Valuation
Trailing PE 19.04 | Forward PE 16.81 | Enterprise Value 11000112077 | Price to Sales(TTM) 1.6 |
Enterprise Value 11000112077 | Price to Sales(TTM) 1.6 | ||
Enterprise Value to Revenue 2.48 | Enterprise Value to EBITDA 7.85 | Shares Outstanding 496646016 | Shares Floating 492857091 |
Shares Outstanding 496646016 | Shares Floating 492857091 | ||
Percent Insiders 1.03 | Percent Institutions 101.48 |
Analyst Ratings
Rating 3 | Target Price 14.86 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold 8 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Elanco Animal Health
Company Overview
History and Background
Elanco Animal Health was founded in 1954 as a division of Eli Lilly and Company. It focused on animal health products and was later spun off as an independent company in 2019. Elanco has grown through acquisitions and organic growth to become a leading animal health company.
Core Business Areas
- Companion Animal Health: Focuses on products for pets, including parasiticides, vaccines, and therapeutics.
- Food Animal Health: Focuses on products for livestock, including poultry, swine, and cattle, offering solutions for disease prevention, growth promotion, and overall animal well-being.
Leadership and Structure
Elanco is led by Jeff Simmons (President and CEO). The organizational structure includes functional departments such as R&D, Commercial, Manufacturing, and Finance.
Top Products and Market Share
Key Offerings
- Interceptor Plus: A parasiticide for dogs. Competes with products from Zoetis (Revolution) and Merck (Bravecto). Market share is estimated to be around 15% of the canine parasiticide market with annual revenues around $300 million.
- Credelio: An oral flea and tick preventative for dogs and cats. Key competitors include Bravecto (Merck) and NexGard (Boehringer Ingelheim). Market Share is about 8% with revenue generation of 200 million per year.
- Rumensin: An ionophore used to improve feed efficiency in cattle. Competes with other feed additives. Market share estimation is unavailable but it is a key source of revenue for the company.
Market Dynamics
Industry Overview
The animal health industry is growing due to increased pet ownership, rising demand for animal protein, and advancements in veterinary medicine. The market is characterized by innovation, consolidation, and regulatory oversight.
Positioning
Elanco is a major player in the animal health industry, with a broad portfolio of products and a global presence. Its competitive advantages include its R&D capabilities, manufacturing expertise, and distribution network.
Total Addressable Market (TAM)
The global animal health market is projected to reach over $70 billion. Elanco is well-positioned to capture a significant portion of this TAM, focusing on both companion and food animal segments.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Global presence and distribution network
- Diverse product portfolio
- R&D capabilities
- Expertise in both companion and food animal health
Weaknesses
- High debt levels post-Bayer acquisition
- Integration challenges from acquisitions
- Reliance on key products
- Exposure to regulatory risks
- Fluctuations in currency exchange rates
Opportunities
- Expansion in emerging markets
- Development of novel therapeutics
- Growth in the pet health market
- Strategic partnerships and collaborations
- Increasing demand for sustainable animal protein
Threats
- Competition from larger players
- Generic erosion of key products
- Economic downturns affecting pet ownership
- Disease outbreaks impacting livestock
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- ZTS
- MRK
- BMY
Competitive Landscape
Elanco faces intense competition from larger, more diversified players like Zoetis and Merck. Elanco's advantages include its focus on animal health and its strong brand recognition. However, it needs to manage its debt and successfully integrate acquisitions to remain competitive.
Major Acquisitions
Bayer Animal Health
- Year: 2020
- Acquisition Price (USD millions): 6890
- Strategic Rationale: Expanded Elanco's product portfolio and geographic reach, creating the second-largest animal health company globally.
Growth Trajectory and Initiatives
Historical Growth: Elanco's growth has been driven by organic sales and acquisitions, particularly the acquisition of Bayer Animal Health. The company has focused on expanding its product portfolio and geographic reach.
Future Projections: Analysts project continued growth for Elanco, driven by the increasing demand for animal health products and the company's focus on innovation. Revenue growth is expected to be in the mid-single digits percentage annually.
Recent Initiatives: Elanco has been focused on integrating the Bayer Animal Health business, launching new products, and investing in R&D.
Summary
Elanco is a prominent player in the animal health industry, benefiting from a strong brand and diverse product portfolio. However, the company faces challenges related to its high debt levels and integration efforts following the Bayer acquisition. To capitalize on growth opportunities, Elanco needs to focus on innovation and strategic partnerships while managing its financial risks and keeping tabs on generic competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elanco Animal Health
Exchange NYSE | Headquaters Greenfield, IN, United States | ||
IPO Launch date 2018-09-20 | President, CEO & Director Mr. Jeffrey N. Simmons | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9000 | Website https://www.elanco.com |
Full time employees 9000 | Website https://www.elanco.com | ||
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.